Urgent.News

What's breaking now, across hundreds of outlets.

Continued

AI

US restricts remote access to data centers using advanced AI chips

WASHINGTON (Kyodo) -- The U.S. government said Monday it will restrict remote access to overseas data centers powered by advanced artificial intellige

  • U.S. tightens remote access to overseas data centers with AI chips
  • Companies in China can't use American AI tech for AI model training
  • Licenses required for exporting advanced AI chips to specific countries

Health & Medicine

The cost of diabetes is showing up earlier than many expect

Nearly one in nine adults worldwide, or 589 million people, now live with diabetes, according to the International Diabetes Federation’s 2025 Diabetes Atlas, and around 252 million of them don’t know it. Many are only diagnosed once complications have begun, and the most serious of these, heart attack and stroke, often follow years of…

Health & Medicine

Public lab system vital to health care

Owing to long lineups outside lab sites across southern Manitoba, Dynacare is asking its customers to wait in their cars or other locations before their appointment. While Dynacare, a private, […]

  • Dynacare lab tests vital for patient care
  • Understaffing and labor dispute cause delays
  • Manitoba should invest in public lab system

Culture

Dance group giving Molly her moment

Margie Gillis’s first word was “yes.” “My mother said it scared the wits out of her,” the 73-year-old Canadian dancer and choreographer says with a laugh, sitting in the seats […]

  • Margie Gillis' "The Whole Bloomin' Thing" gives Molly Bloom her ensemble moment.
  • Inspired by Joyce's character's famous "Yes," the piece explores her psyche.
  • Winnipeg Contemporary Dancers present the adapted work this week.

Health & Medicine

Novofactory Receives Flawless FDA Assessment

CG Bio, a regenerative medicine company, said its Novofactory facility in Hwaseong, Gyeonggi Province, concluded an on-site FDA inspection of human tissue operations with zero findings.

  • FDA gave CG Bio's Novofactory facility a flawless assessment in September.
  • Inspection covered quality management, donor verification, and traceability.
  • Novofactory set for completion in March will boost business and partnerships.

Health & Medicine

Hanmi Drugs Show Promise in Phase 1 Trials

Hanmi Pharmaceutical said two next-generation anticancer drug candidates under development demonstrated both antitumor activity and safety in global Phase 1 clinical trials.

  • Hanmi's HM97662 and BH3120 showed promise in Phase 1 trials.
  • HM97662 targets EZH1 and EZH2 proteins to suppress gene expression.
  • BH3120 is an immuno-oncology candidate with positive liver toxicity results.
Continue reading →